Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Kamboj, Amit ^a,b   Lu, Ping ^a,b   Cossoy, Michael B ^a   Stobart, Jillian L ^a,b   Dolhun, Brian A ^a,b   Kauppinen, Tiina M ^a   de Murcia, Gilbert ^c   Anderson, Christopher M ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

CD11b; CD4; Demyelination; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neuroinflammation; PARP 1; PARP 2; Th1; Th17

Indexed keywords

CD11B ANTIGEN; FREUND ADJUVANT; MYCOBACTERIUM VACCINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; PERTUSSIS TOXIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SPINE BARRIER; CONTROLLED STUDY; DEMYELINATION; FEMALE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; GENOTYPE; IMMUNIZATION; INFLAMMATORY INFILTRATE; MEMBRANE PERMEABILITY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; NULL ALLELE; PARP 2 GENE; PROTEIN FUNCTION; TH1 CELL; TH17 CELL; UPREGULATION;

EID: 84876728257     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-49     Document Type: Article

References (25)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992, 31:333-336. 10.1002/ana.410310317, 1637140.
2. Girouard N, Soucy N. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence 2011, 5:101-108. 3063656, 21448467.
3. Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 2003, 24:131-138. 10.1016/S0165-6147(03)00028-2, 12628358.
4. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001, 14:271-278. 10.1097/00019052-200106000-00003, 11371748.
5. Link H, Xiao BG. Rat models as tool to develop new immunotherapies. Immunol Rev 2001, 184:117-128. 10.1034/j.1600-065x.2001.1840111.x, 11918681.
6. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays 2004, 26:882-893. 10.1002/bies.20085, 15273990.
7. Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair (Amst) 2004, 3:1103-1108.
8. Ménissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, Schreiber V, Amé JC, Dierich A, LeMeur M, Sabatier L, Chambon P, de Murcia G. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003, 22:2255-2263. 10.1093/emboj/cdg206, 156078, 12727891.
9. Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J, de Murcia G. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002, 277:23028-23036. 10.1074/jbc.M202390200, 11948190.
10. Chiarugi A. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br J Pharmacol 2002, 137:761-770. 10.1038/sj.bjp.0704934, 1573557, 12411406.
11. Scott GS, Kean RB, Mikheeva T, Fabis MJ, Mabley JG, Szabo C, Hooper DC. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N, N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther 2004, 310:1053-1061. 10.1124/jpet.103.063214, 15159442.
12. Cavone L, Aldinucci A, Ballerini C, Biagioli T, Moroni F, Chiarugi A. PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult Scler 2011, 17:794-807. 10.1177/1352458511399113, 21343230.
13. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 2009, 10:958-964. 10.1038/ni.1775, 2746562, 19684606.
14. Selvaraj V, Soundarapandian MM, Chechneva O, Williams AJ, Sidorov MK, Soulika AM, Pleasure DE, Deng W. PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis. J Biol Chem 2009, 284:26070-26084. 10.1074/jbc.M109.013474, 2758007, 19628872.
15. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002, 125:1297-1308. 10.1093/brain/awf133, 12023318.
16. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol 2005, 158:213-221. 10.1016/j.jneuroim.2004.09.006, 15589056.
17. Touil T, Ciric B, Ventura E, Shindler KS, Gran B, Rostami A. Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis. J Neurol Sci 2008, 271:191-202. 10.1016/j.jns.2008.04.030, 2723951, 18544456.
18. Sanna V, Di Giacomo A, La Cava A, Lechler RI, Fontana S, Zappacosta S, Matarese G. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003, 111:241-250. 151876, 12531880.
19. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669. 10.1016/S0092-8674(00)80702-3, 10761931.
20. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133. 10.1016/j.cell.2006.07.035, 16990136.
21. Iwashita A, Tojo N, Matsuura S, Yamazaki S, Kamijo K, Ishida J, Yamamoto H, Hattori K, Matsuoka N, Mutoh S. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazo linone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. J Pharmacol Exp Ther 2004, 310:425-436. 10.1124/jpet.104.066944, 15075382.
22. Jelezcova E, Trivedi RN, Wang XH, Tang JB, Brown AR, Goellner EM, Schamus S, Fornsaglio JL, Sobol RW. Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage. Mutat Res 2010, 686:57-67. 10.1016/j.mrfmmm.2010.01.016, 2834876, 20096707.
23. Sunderland PT, Dhami A, Mahon MF, Jones LA, Tully SR, Lloyd MD, Thompson AS, Javaid H, Martin NM, Threadgill MD. Synthesis of 4-alkyl-, 4-aryl- and 4-arylamino-5-aminoisoquinolin-1-ones and identification of a new PARP-2 selective inhibitor. Org Biomol Chem 2011, 9:881-891. 10.1039/c0ob00665c, 21127791.
24. Nasta F, Laudisi F, Sambucci M, Rosado MM, Pioli C. Increased Foxp3+ regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency. J Immunol 2010, 184:3470-3477. 10.4049/jimmunol.0901568, 20208002.
25. Yélamos J, Monreal Y, Saenz L, Aguado E, Schreiber V, Mota R, Fuente T, Minguela A, Parrilla P, de Murcia G, Almarza E, Aparicio P, Ménissier-de Murcia J. PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes. EMBO J 2006, 25:4350-4360. 10.1038/sj.emboj.7601301, 1570435, 16946705.